Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trials Report for January 2015

    ... Study Coordinator Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing ...

    Page last updated 12/30/2014 - 10:45am.

  2. MDS and MDS/MPN: Past, Present, and Future 2014 American Society of Hematology (ASH) Satellite Symposium Summary for Patients and Families

    ... agents (HMAs) azacitidine (Vidaza®) and decitabine (Dacogen®) inhibit DNA methylation so that DNA sequences can ...

    Page last updated 03/13/2015 - 5:00pm.

  3. Clinical Trials Report for December 2014

    ... Study Coordinator Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing ...

    Page last updated 11/25/2014 - 3:33pm.

  4. Clinical Trial Basics

    ... bone marrow failure diseases. These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide ...

    Page last updated 01/20/2015 - 4:58pm.

  5. Clinical Trial Basics

    ... bone marrow failure diseases. These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide ...

    Page last updated 01/20/2015 - 4:46pm.

  6. Clinical Trials Report for April 2014

    ... Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine Observation in Treating Older Patients With Newly Diagnosed Acute ... daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute ...

    Page last updated 04/18/2014 - 3:36pm.

  7. Patient Education Materials

    ... drugs for MDS – azacitidine (Vidaza®), decitabine (Dacogen®) and lenalidomide (Revlimid®). Read about ...

    Page last updated 11/06/2013 - 4:28pm.

  8. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... agents (HMA), azacitidine (Vidaza®), and decitabine (Dacogen®)? The overall response rate to HMA based ... that enzyme is called uridine cytidine kinase (UCK), and for decitabine, it’s called deoxycitadine kinase (DCK). So these kinases causing ...

    Interview last updated 06/17/2014 - 9:15am.

  9. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... drugs that impact DNA methylation (e.g., azacytidine, decitabine ) and drugs that impact histone acetylation (e.g., vorinostat, ...

    Interview last updated 02/01/2013 - 4:22pm.

  10. Treating Higher-Risk Myelodysplastic Syndromes

    ... like azacitidine (Vidaza®) or decitabine (Dacogen®). If patients have very high-risk MDS, bordering on ... standard of care treatments for MDS includes azacitidine, decitabine, or lenalidomide (Revlimid®). Clinical research with new ...

    Interview last updated 05/18/2012 - 1:55pm.